Gujarat Kidney and Super Speciality Limited announced robust financial results for the half-year ended September 30, 2026 (H1 FY27). Consolidated revenues surged by 157% year-on-year to INR72.4 crores, already representing 88% of the full FY26 revenue. EBITDA also saw a significant increase of 35% to INR18.6 crores, with an improved EBITDA margin of approximately 25.7%. PAT grew by 44% to INR11.9 crores.
Gujarat Kidney and Super Speciality Limited Reports Strong H1 FY27 Performance
Gujarat Kidney and Super Speciality Limited has disclosed its financial results for the first half of FY27 (H1 FY27), ending September 30, 2026, showcasing significant growth across key performance indicators. The company highlighted a substantial 157% year-on-year increase in consolidated revenues from operations, reaching INR72.4 crores, a notable achievement that stands at 88% of its total revenue for the full FY26.
EBITDA and PAT Growth
EBITDA for H1 FY27 stood at INR18.6 crores, marking a 35% increase compared to the previous year. The EBITDA margin for the period was approximately 25.7%. Profit After Tax (PAT) also demonstrated strong upward momentum, growing by 44% year-on-year to INR11.9 crores, with a PAT margin of approximately 16.5%.
Quarter 2 Momentum
The second quarter of FY27 (Q2 FY27) continued this positive trend, with revenue growing 11% quarter-on-quarter and an impressive 195% year-on-year to INR38.1 crores. EBITDA for the quarter increased by 22% quarter-on-quarter to INR10.2 crores, with the EBITDA margin expanding to 26.8% from 24.4% in the previous quarter. Operating costs saw a 24% quarter-on-quarter increase.
Financial Health and Strategic Priorities
As of September 30, 2026, the company’s net worth was reported at INR263.6 crores, with a net cash position of INR32.2 crores against borrowings of INR17.3 crores. During the half-year, the company deployed approximately INR16.7 crores for acquisitions and INR6.2 crores in capital expenditure, while operating cash flow turned positive. Key priorities moving forward include upgrading existing facilities, pursuing inorganic growth opportunities, and capturing a larger share of the patient journey across all service touchpoints.
International Expansion
The company has also made strides in international expansion, acquiring a 51% stake in an established polyclinic in Dubai, which has an existing revenue base of approximately INR20 crores. This move is expected to provide access to international patients and serve as a gateway for medical tourism to India.
Source: BSE
